Nevertheless, precisely because of its diverse roles beyond apoptosis inhibition, targeting Bcl-xL, particularly in combination with other therapeutic agents, represents a promising strategy to overcome drug resistance and improve cancer treatment outcomes. This evidence concerns the gene BCL2L1 and cancer.